Structure genomics of SARS-CoV-2 and its Omicron variant:drug design templates for COVID-19  

作　　者：Can-rong Wu Wan-chao Yin Yi Jiang H.Eric Xu 

机构地区：[1]The CAS Key Laboratory of Receptor Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China [2]School of Life Science and Technology,ShanghaiTech University,Shanghai 201210,China

出　　处：《Acta Pharmacologica Sinica》2022年第12期3021-3033,共13页中国药理学报（英文版）

基　　金：This work was partially supported by Ministry of Science and Technology(China)grants(2018YFA0507002 to HEX);the Shanghai Municipal Science and Technology Major Project(2019SHZDZX02 to HEX);the CAS Strategic Priority Research Program(XDB08020303 to HEX);the National Natural Science Foundation of China(31770796 to YJ);the Youth Innovation Promotion Association of CAS(No.2021278 to WCY).

摘　　要：Coronavirus disease 2019(COVID-19),caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),has brought an unprecedented public health crisis and persistently threatens to humanity.With tireless efforts from scientists around the world,understanding of the biology of coronavirus has been greatly enhanced over the past 2 years.Structural biology has demonstrated its powerful impact on uncovering structures and functions for the vast majority of SARS-CoV-2 proteins and guided the development of drugs and vaccines against COVID-19.In this review,we summarize current progress in the structural biology of SARS-CoV-2 and discuss important biological issues that remain to be addressed.We present the examples of structure-based design of Pfizer’s novel anti-SARS-CoV-2 drug PF-07321332(Paxlovid),Merck’s nucleotide inhibitor molnupiravir(Lagevrio),and VV116,an oral drug candidate for COVID-19.These examples highlight the importance of structure in drug discovery to combat COVID-19.We also discussed the recent variants of Omicron and its implication in immunity escape from existing vaccines and antibody therapies.

关 键 词：PFIZER IMMUNITY MERCK 

分 类 号：R96[医药卫生—药理学]